MT2025-51: A RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FOR LARGE B-CELL LYMPHOMA (ALPHA3)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- 18 years of age or older - diagnosed with certain types of large B-cell lymphoma (LBCL) - completed standard first-line treatment without needing additional therapy - cancer is in complete remission or partial remission suitable for observation after first-line treatment

Exclusion Criteria:

- lymphoma has spread to the brain or spinal cord, or developed from another type of cancer - previously treated with anti-CD19 therapy - active autoimmune disease or a serious infection requiring treatment - another cancer or bone marrow disorder diagnosed within the past 3 years

Conditions & Interventions

Interventions:
Drug: Cyclophosphamide, Drug: Fludarabine, Device: Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™, Genetic: cemacabtagene ansegedleucel
Conditions:
Cancer
Keywords:
Clinics and Surgery Center (CSC), Cancer, large B-cell lymphoma, LBCL

More Information

Description: This study is for adults with large B-cell lymphoma whose cancer responded to standard treatment but still shows small amounts of disease on a specialized blood test. Participants will be randomly assigned to receive either an investigational CAR T-cell therapy or standard follow-up observation to compare safety and how well each approach helps prevent the lymphoma from returning.
Study Contact: Veronika Bachanova - bach0173@umn.edu
Principal Investigator: Veronika Bachanova, MD
Phase: PHASE2
IRB Number: STUDY00027450